Recommendations for the treatment of multiple sclerosis with disease-modifying drugs during the COVID-19 pandemic
The novel coronavirus 2019 (COVID-19) and the subsequent pandemic present a challenge to neurologists treating patients with multiple sclerosis (MS) worldwide. Many national professional bodies have responded rapidly by issuing guidelines for the COVID-19 pandemic, primarily focused on MS disease-m...
Saved in:
Main Authors: | R. Kizlaitienė, N. Giedraitienė, I. Sereikė, J. Liutkienė, L. Leščinskienė, G. Kaubrys |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2020-06-01
|
Series: | Neurologijos seminarai |
Subjects: | |
Online Access: | https://www.journals.vu.lt/neurologijos_seminarai/article/view/27741 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Adherence to disease modifying therapies in patients with multiple sclerosis
by: D. Pileckė, et al.
Published: (2019-06-01) -
The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
by: I. Jonušaitė, et al.
Published: (2024-03-01) -
Administration and Monitoring Burden of High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis: A Delphi Consensus of Clinical Experts from Saudi Arabia
by: Seraj Makkawi, et al.
Published: (2025-01-01) -
Treatment of Multiple Sclerosis with Cladribine Tablets: Literature Review and the Guidance of the Lithuanian Association of Neurologists
by: R. Kizlaitienė, et al.
Published: (2024-03-01) -
Multiple sclerosis: overview of orally administrated disease-modifying drugs. Do genetics influence the success of treatment?
by: A. Ovčinikova, et al.
Published: (2019-03-01)